{ "instance": { "acst-20220331.htm": { "axisCustom": 0, "axisStandard": 24, "contextCount": 229, "dts": { "calculationLink": { "local": [ "acst-20220331_cal.xml" ] }, "definitionLink": { "local": [ "acst-20220331_def.xml" ] }, "inline": { "local": [ "acst-20220331.htm" ] }, "labelLink": { "local": [ "acst-20220331_lab.xml" ] }, "presentationLink": { "local": [ "acst-20220331_pre.xml" ] }, "schema": { "local": [ "acst-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 544, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 17, "http://www.acastipharma.com/20220331": 1, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 23 }, "keyCustom": 57, "keyStandard": 264, "memberCustom": 51, "memberStandard": 32, "nsprefix": "acst", "nsuri": "http://www.acastipharma.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Note 5 - Receivables", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote5Receivables1", "shortName": "Note 5 - Receivables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Note 6 - Short-term Investments", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestments", "shortName": "Note 6 - Short-term Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Note 7 - Impairment Loss Intangible Assets", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote7ImpairmentLossIntangibleAssets", "shortName": "Note 7 - Impairment Loss Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Note 8 - Assets Held for Sale", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSale", "shortName": "Note 8 - Assets Held for Sale", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "acst:GovernmentAssistanceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Note 9 - Government Assistance", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistance1", "shortName": "Note 9 - Government Assistance", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "acst:GovernmentAssistanceTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Note 10 - Trade and Other Payables", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote10TradeAndOtherPayables", "shortName": "Note 10 - Trade and Other Payables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Note 11 - Derivative Warrant Liabilities", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilities", "shortName": "Note 11 - Derivative Warrant Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Note 12 - Capital and Other Components of Equity", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity", "shortName": "Note 12 - Capital and Other Components of Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Note 13 - Revenues", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-13-revenues", "shortName": "Note 13 - Revenues", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Note 14 - Net Financial Income (expenses)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialIncomeExpenses", "shortName": "Note 14 - Net Financial Income (expenses)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Balance Sheets", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Note 15 - Stock Based Compensation", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation", "shortName": "Note 15 - Stock Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Note 16 - Loss Per Share", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-16-loss-per-share", "shortName": "Note 16 - Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Note 17 - Supplemental Cash Flow Disclosure", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure", "shortName": "Note 17 - Supplemental Cash Flow Disclosure", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Note 19 - Financial Instruments", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-19-financial-instruments", "shortName": "Note 19 - Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Note 20 - Commitments and Contingencies", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingencies", "shortName": "Note 20 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Note 21 - Subsequent Events", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-21-subsequent-events-", "shortName": "Note 21 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "acst:PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-tables", "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "acst:PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Note 4 - Acquisition of Grace (Tables)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceTables", "shortName": "Note 4 - Acquisition of Grace (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Note 5 - Receivables (Tables)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote5ReceivablesTables", "shortName": "Note 5 - Receivables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Consolidated Statements of Loss and Comprehensive Loss", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss", "shortName": "Consolidated Statements of Loss and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Note 6 - Short-term Investments (Tables)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsTables", "shortName": "Note 6 - Short-term Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Note 8 - Assets Held for Sale (Tables)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleTables", "shortName": "Note 8 - Assets Held for Sale (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "acst:GovernmentAssistanceTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "acst:ScheduleOfGovernmentAssistanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Note 9 - Government Assistance (Tables)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceTables", "shortName": "Note 9 - Government Assistance (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "acst:GovernmentAssistanceTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "acst:ScheduleOfGovernmentAssistanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Note 10 - Trade and Other Payables (Tables)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote10TradeAndOtherPayablesTables", "shortName": "Note 10 - Trade and Other Payables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Note 11 - Derivative Warrant Liabilities (Tables)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesTables", "shortName": "Note 11 - Derivative Warrant Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Note 12 - Capital and Other Components of Equity (Tables)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-tables", "shortName": "Note 12 - Capital and Other Components of Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Note 14 - Net Financial Expenses (Tables)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialExpensesTables", "shortName": "Note 14 - Net Financial Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Note 15 - Stock Based Compensation (Tables)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-tables", "shortName": "Note 15 - Stock Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowOperatingCapitalTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Note 17 - Supplemental Cash Flow Disclosure (Tables)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-tables", "shortName": "Note 17 - Supplemental Cash Flow Disclosure (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowOperatingCapitalTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Note 18 - Income Taxes (Tables)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tables", "shortName": "Note 18 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_7f07f5dd-b05a-49ea-ac10-562ac3c8abab", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Consolidated Statements of Changes in Shareholder's Equity", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "shortName": "Consolidated Statements of Changes in Shareholder's Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_7f07f5dd-b05a-49ea-ac10-562ac3c8abab", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_6f6b8e45-deba-4c13-9f42-6adbd0cb3f38", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Note 1 - Nature of Operation (Details Textual)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual", "shortName": "Note 1 - Nature of Operation (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_6f6b8e45-deba-4c13-9f42-6adbd0cb3f38", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_9150dcc5-9899-4e0b-8205-02cd70760666", "decimals": "-3", "lang": null, "name": "us-gaap:AssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "acst:PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_daf1b2b9-5505-459b-83d1-b86b4440cc33", "decimals": "2", "first": true, "lang": null, "name": "acst:PropertyPantAndEquipmentDepreciationRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives and Rates of Equipment (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details", "shortName": "Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives and Rates of Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "acst:PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_daf1b2b9-5505-459b-83d1-b86b4440cc33", "decimals": "2", "first": true, "lang": null, "name": "acst:PropertyPantAndEquipmentDepreciationRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_52dea292-e3da-4126-a434-ab1d92bb7f64", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Intangible Assets (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details", "shortName": "Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_52dea292-e3da-4126-a434-ab1d92bb7f64", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_3cc07819-4485-47e9-82cd-deb548573172", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Note 4 - Acquisition of Grace - Consideration (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails", "shortName": "Note 4 - Acquisition of Grace - Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_e2775c17-1317-45fc-87e9-bcbac98c3b4f", "decimals": "4", "lang": null, "name": "us-gaap:BusinessAcquisitionSharePrice", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Note 4 - Acquisition of Grace - Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails", "shortName": "Note 4 - Acquisition of Grace - Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_e2775c17-1317-45fc-87e9-bcbac98c3b4f", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Note 4 - Acquisition of Grace - Pro Forma Financial Information (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceProFormaFinancialInformationDetails", "shortName": "Note 4 - Acquisition of Grace - Pro Forma Financial Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:InProcessResearchAndDevelopmentPolicy", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_3cc07819-4485-47e9-82cd-deb548573172", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Note 4 - Acquisition of Grace - Schedule of Intangible Assets in Process Research and Development (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails", "shortName": "Note 4 - Acquisition of Grace - Schedule of Intangible Assets in Process Research and Development (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:InProcessResearchAndDevelopmentPolicy", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_5b195e2d-c14a-410a-b235-034d47b949d3", "decimals": "-3", "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Note 4 - Acquisition of Grace (Details Textual)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual", "shortName": "Note 4 - Acquisition of Grace (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2791d12e-5988-4a4f-ba94-431192436546", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "first": true, "lang": null, "name": "acst:SalesTaxReceivablesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Note 5 - Receivables - Receivables (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote5ReceivablesReceivablesDetails", "shortName": "Note 5 - Receivables - Receivables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "div", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "first": true, "lang": null, "name": "acst:SalesTaxReceivablesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Note 6 - Short-term Investments - Marketable Securities (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetails", "shortName": "Note 6 - Short-term Investments - Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_837dce38-d5f6-4d58-a063-3d6baa9b3d3f", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:InvestmentInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Note 6 - Short-term Investments - Marketable Securities (Details) (Parentheticals)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetailsParentheticals", "shortName": "Note 6 - Short-term Investments - Marketable Securities (Details) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_837dce38-d5f6-4d58-a063-3d6baa9b3d3f", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:InvestmentInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Note 7 - Impairment Loss Intangible Assets (Details Textual)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote7ImpairmentLossIntangibleAssetsDetailsTextual", "shortName": "Note 7 - Impairment Loss Intangible Assets (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "acst:ImpairmentOfOtherAssetsAndPrepaids", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Note 8 - Assets Held for Sale (Details Textual)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleDetailsTextual", "shortName": "Note 8 - Assets Held for Sale (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Note 8 - Assets Held for Sale - Summary of Assets Held for Sale (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails", "shortName": "Note 8 - Assets Held for Sale - Summary of Assets Held for Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "lang": null, "name": "acst:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "acst:GovernmentAssistanceTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_b6154516-4b06-4390-8522-3da4b7978b3e", "decimals": "-3", "first": true, "lang": null, "name": "acst:AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP", "reportCount": 1, "unique": true, "unitRef": "U_CAD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Note 9 - Government Assistance (Details Textual)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceDetailsTextual", "shortName": "Note 9 - Government Assistance (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "acst:GovernmentAssistanceTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_b6154516-4b06-4390-8522-3da4b7978b3e", "decimals": "-3", "first": true, "lang": null, "name": "acst:AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP", "reportCount": 1, "unique": true, "unitRef": "U_CAD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "acst:ScheduleOfGovernmentAssistanceTableTextBlock", "div", "acst:GovernmentAssistanceTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "first": true, "lang": null, "name": "acst:InvestmentTaxCreditReceivable", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Note 9 - Government Assistance - Government Assistance (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceGovernmentAssistanceDetails", "shortName": "Note 9 - Government Assistance - Government Assistance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "acst:ScheduleOfGovernmentAssistanceTableTextBlock", "div", "acst:GovernmentAssistanceTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "first": true, "lang": null, "name": "acst:InvestmentTaxCreditReceivable", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock", "div", "acst:GovernmentAssistanceTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_9dae6bba-7ea6-4db9-a65d-ad27cbbcf1fa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:TaxCreditCarryforwardAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Note 9 - Government Assistance - Unrecognized Federal Tax Credits Expirations (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "shortName": "Note 9 - Government Assistance - Unrecognized Federal Tax Credits Expirations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock", "div", "acst:GovernmentAssistanceTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_9dae6bba-7ea6-4db9-a65d-ad27cbbcf1fa", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:TaxCreditCarryforwardAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableTradeCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Note 10 - Trade and Other Payables - Trade and Other Payables (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote10TradeAndOtherPayablesTradeAndOtherPayablesDetails", "shortName": "Note 10 - Trade and Other Payables - Trade and Other Payables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableTradeCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Note 11 - Derivative Warrant Liabilities (Details Textual)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual", "shortName": "Note 11 - Derivative Warrant Liabilities (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_320cf764-a9bf-4d79-9039-a86e69e4a623", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100050 - Disclosure - Note 1 - Nature of Operations", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-1-nature-of-operations", "shortName": "Note 1 - Nature of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_f0e213ce-2446-496b-bac8-62e7ff32fffd", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Note 11 - Derivative Warrant Liabilities - Changes in Fair Value (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesChangesInFairValueDetails", "shortName": "Note 11 - Derivative Warrant Liabilities - Changes in Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_3433e6a5-dcd1-4b8e-8794-a91787b80071", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_e6f65541-6452-4262-8469-3d84ee79ade7", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "U_CAD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Note 11 - Derivative Warrant Liabilities - Assumptions (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesAssumptionsDetails", "shortName": "Note 11 - Derivative Warrant Liabilities - Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_e6f65541-6452-4262-8469-3d84ee79ade7", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "U_CAD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_c3712909-da01-4dd9-aa28-b911fb36270a", "decimals": "0", "first": true, "lang": null, "name": "acst:AtthemarketSalesAgreementCommonStockMaximumAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Note 12 - Capital and Other Components of Equity (Details Textual)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "shortName": "Note 12 - Capital and Other Components of Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_c3712909-da01-4dd9-aa28-b911fb36270a", "decimals": "0", "first": true, "lang": null, "name": "acst:AtthemarketSalesAgreementCommonStockMaximumAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Note 12 - Capital and Other Components of Equity - Warrants (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-warrants-details", "shortName": "Note 12 - Capital and Other Components of Equity - Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "lang": null, "name": "us-gaap:WarrantsAndRightsOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossRealized", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Note 14 - Net Financial Expenses - Financial Income (Expenses) (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialExpensesFinancialIncomeExpensesDetails", "shortName": "Note 14 - Net Financial Expenses - Financial Income (Expenses) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossRealized", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "acst:UnrecognizedCompensationCostRelatedToNonVestedShareOptions", "reportCount": 1, "unique": true, "unitRef": "U_CAD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Note 15 - Stock Based Compensation (Details Textual)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual", "shortName": "Note 15 - Stock Based Compensation (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "acst:UnrecognizedCompensationCostRelatedToNonVestedShareOptions", "reportCount": 1, "unique": true, "unitRef": "U_CAD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "acst:ScheduleOfNonvestedOptionActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Note 15 - Stock-based Compensation - Activities Within the Stock Option Plan (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details", "shortName": "Note 15 - Stock-based Compensation - Activities Within the Stock Option Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_65a1d67a-4f87-4846-b44d-9bb12b43fde2", "decimals": "2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_75f337ce-a1da-410f-a344-fdc4bfbd1e50", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Note 15 - Stock Based Compensation - Compensation Expense (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-compensation-expense-details", "shortName": "Note 15 - Stock Based Compensation - Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_a9bc6d95-5044-4529-b0d6-dd8c66c2a457", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "acst:ScheduleOfNonvestedOptionActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_e948fa31-6381-43cb-a632-53bc62bc9fdd", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Note 15 - Stock-based Compensation - Summary of the non-vested stock option activity (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote15StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails", "shortName": "Note 15 - Stock-based Compensation - Summary of the non-vested stock option activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "acst:ScheduleOfNonvestedOptionActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_e948fa31-6381-43cb-a632-53bc62bc9fdd", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_ac0d7112-d4a8-4a09-9cf5-7c0c8e944c67", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Note 15 - Stock-based Compensation - Assumptions (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-assumptions-details", "shortName": "Note 15 - Stock-based Compensation - Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_ac0d7112-d4a8-4a09-9cf5-7c0c8e944c67", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100740 - Disclosure - Note 15 - Stock-based Compensation - Outstanding and Exercisable Options (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details", "shortName": "Note 15 - Stock-based Compensation - Outstanding and Exercisable Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:CashFlowOperatingCapitalTableTextBlock", "div", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncreaseDecreaseInReceivables", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100750 - Disclosure - Note 17 - Supplemental Cash Flow Disclosure - Changes in Working Capital Items (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-changes-in-working-capital-items-details", "shortName": "Note 17 - Supplemental Cash Flow Disclosure - Changes in Working Capital Items (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:CashFlowOperatingCapitalTableTextBlock", "div", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncreaseDecreaseInReceivables", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100770 - Disclosure - Note 18 - Income taxes - Income Tax (Recovery) Expense (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote18IncomeTaxesIncomeTaxRecoveryExpenseDetails", "shortName": "Note 18 - Income taxes - Income Tax (Recovery) Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100780 - Disclosure - Note 18 - Income Taxes - Reconciliation of Effective Tax Rate (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details", "shortName": "Note 18 - Income Taxes - Reconciliation of Effective Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": "4", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100790 - Disclosure - Note 18 - Income Taxes - Net Deferred Tax Assets (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details", "shortName": "Note 18 - Income Taxes - Net Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0c380609-561f-4b71-8da8-ad224429980d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_58c81668-996d-4d38-a95c-82a7d72e413d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:TaxCreditCarryforwardAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100800 - Disclosure - Note 18 - Income Taxes - Tax Attributes and Temporary Differences Available to Reduce Future Years' Taxable Income (Details)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details", "shortName": "Note 18 - Income Taxes - Tax Attributes and Temporary Differences Available to Reduce Future Years' Taxable Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_58c81668-996d-4d38-a95c-82a7d72e413d", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:TaxCreditCarryforwardAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_5a1e36aa-35df-4f87-bd2c-dd6d33ad3a9c", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100820 - Disclosure - Note 20 - Commitments and Contingencies (Details Textual)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual", "shortName": "Note 20 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_5a1e36aa-35df-4f87-bd2c-dd6d33ad3a9c", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2a916132-5932-4710-a611-080bd26c195c", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100830 - Disclosure - 21. Subsequent events (Additional Information) (Details Textual)", "role": "http://www.acastipharma.com/20220331/taxonomy/role/Disclosure21SubsequentEventsAdditionalInformationDetailsTextual", "shortName": "21. Subsequent events (Additional Information) (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_0b23cdbe-3949-40de-a988-3b29d8a01f1b", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Note 3 - Recent Accounting Pronouncements", "role": "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-3-recent-accounting-pronouncements", "shortName": "Note 3 - Recent Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Note 4 - Acquisition of Grace", "role": "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGrace", "shortName": "Note 4 - Acquisition of Grace", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "acst-20220331.htm", "contextRef": "C_2261c812-c863-4c54-9c46-13d795e57504", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 85, "tag": { "acst_ATMTransactionCostsIncludedInTradeAndOtherPayables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of ATM transaction costs included in trade and other payables.", "label": "ATM transaction costs included in trade and other payables", "terseLabel": "ATM transaction costs included in trade and other payables" } } }, "localname": "ATMTransactionCostsIncludedInTradeAndOtherPayables", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-noncash-transactions-details" ], "xbrltype": "monetaryItemType" }, "acst_AdditionalLeaseRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional lease renewal term", "label": "Additional lease renewal term" } } }, "localname": "AdditionalLeaseRenewalTerm", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "durationItemType" }, "acst_AdjustmentsToNetAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments To Net Assets", "label": "Adjustments To Net Assets", "terseLabel": "Adjustments to net assets" } } }, "localname": "AdjustmentsToNetAssets", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual" ], "xbrltype": "monetaryItemType" }, "acst_AmortizablePatentsAndLicenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortizable patents and licenses", "label": "Amortizable Patents and Licenses", "terseLabel": "Amortizable patents and licenses" } } }, "localname": "AmortizablePatentsAndLicenses", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "acst_AssetsHeldForSalePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for assets held for sale policy.", "label": "Assets Held For Sale Policy [Policy Text Block]", "terseLabel": "Assets held for sale" } } }, "localname": "AssetsHeldForSalePolicyTextBlock", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "acst_AtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information regarding an at-the-market offering.", "label": "At-the-market Offering [Member]", "terseLabel": "At-the-market Offering [Member]" } } }, "localname": "AtTheMarketOfferingMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/Disclosure21SubsequentEventsAdditionalInformationDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "acst_AtthemarketSalesAgreementCommonStockMaximumAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The maximum amount of common stock that can be sold under the at-the-market sales agreement.", "label": "acst_AtthemarketSalesAgreementCommonStockMaximumAmount", "terseLabel": "At-the-market Sales Agreement, Common Stock, Maximum Amount" } } }, "localname": "AtthemarketSalesAgreementCommonStockMaximumAmount", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "acst_AtthemarketSalesAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The term of the at-the-market sales agreement.", "label": "acst_AtthemarketSalesAgreementTerm", "terseLabel": "At-the-market Sales Agreement, Term (Year)" } } }, "localname": "AtthemarketSalesAgreementTerm", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "durationItemType" }, "acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of each sale that is to be paid to the underwriter under the at-the-market sales agreement.", "label": "acst_AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales", "terseLabel": "At-the-market Sales Agreement, Underwriter Fees, Percentage of Sales" } } }, "localname": "AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "percentItemType" }, "acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of award in non-dilutive and non-repayable funding from National Research Council of Canada Industrial Research Assistance Program.", "label": "acst_AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP", "terseLabel": "Award in Non-dilutive and Non-repayable Funding From NRC IRAP" } } }, "localname": "AwardInNondilutiveAndNonrepayableFundingFromNRCIRAP", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceDetailsTextual" ], "xbrltype": "monetaryItemType" }, "acst_BrokerWarrantsIssuedDecember2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents broker warrants issued December 2017.", "label": "Broker Warrants Issued December 2017 [Member]", "terseLabel": "Broker Warrants Issued December 2017 [Member]" } } }, "localname": "BrokerWarrantsIssuedDecember2017Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-warrants-details" ], "xbrltype": "domainItemType" }, "acst_BrokerWarrantsIssuedMay2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents broker warrants issued May 2018.", "label": "Broker Warrants Issued May 2018 [Member]", "terseLabel": "Broker Warrants Issued May 2018 [Member]" } } }, "localname": "BrokerWarrantsIssuedMay2018Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-warrants-details" ], "xbrltype": "domainItemType" }, "acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and accrued expenses incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "acst_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "acst_CanadianDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "information pertaining to Canadian deposits.", "label": "Canadian Deposits [Member]", "terseLabel": "Canadian Deposits [Member]" } } }, "localname": "CanadianDepositsMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetailsParentheticals" ], "xbrltype": "domainItemType" }, "acst_ChiefExecutiveOfficerAndChiefOperatingOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the chief executive officer (CEO) and the chief operating officer (COO).", "label": "Chief Executive Officer and Chief Operating Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerAndChiefOperatingOfficerMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "domainItemType" }, "acst_ClassOfWarrantOrRightExercisedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights exercised during period.", "label": "acst_ClassOfWarrantOrRightExercisedDuringPeriod", "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)" } } }, "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "sharesItemType" }, "acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share of warrants or rights exercised during period.", "label": "acst_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice", "terseLabel": "Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "perShareItemType" }, "acst_CommissionCostsRelatedToShareSale": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of commission costs recognized during the period related to share sale.", "label": "acst_CommissionCostsRelatedToShareSale", "terseLabel": "Commission Costs Related to Share Sale" } } }, "localname": "CommissionCostsRelatedToShareSale", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "acst_CommonClassDAndCommonClassEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, B, or C, representing ownership interest in a corporation.", "label": "Common Class D and Common Class E [Member]", "terseLabel": "Common Class D and Common Class E [Member]" } } }, "localname": "CommonClassDAndCommonClassEMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "domainItemType" }, "acst_CommonStockConversionRateIntoClassA": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The rate at which shares are convertible into one share of class A common stock.", "label": "acst_CommonStockConversionRateIntoClassA", "terseLabel": "Common Stock, Conversion Rate into Class A" } } }, "localname": "CommonStockConversionRateIntoClassA", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "pureItemType" }, "acst_CommonStockDividendRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on common stock.", "label": "acst_CommonStockDividendRatePercentage", "terseLabel": "Common Stock, Dividend Rate, Percentage" } } }, "localname": "CommonStockDividendRatePercentage", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "percentItemType" }, "acst_CommonStockRedemptionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount to be paid per share at which the common stock of an entity is redeemed or may be called at.", "label": "acst_CommonStockRedemptionPricePerShare", "terseLabel": "Common Stock, Redemption Price Per Share (in CAD per share)" } } }, "localname": "CommonStockRedemptionPricePerShare", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "perShareItemType" }, "acst_CommonStockVotesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of votes per one share of common stock.", "label": "acst_CommonStockVotesPerShare", "terseLabel": "Common Stock, Votes Per Share" } } }, "localname": "CommonStockVotesPerShare", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "integerItemType" }, "acst_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents consultant.", "label": "Consultant [Member]", "terseLabel": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "acst_CostRelatedToProspectusSupplementAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost Related to Prospectus Supplement Amount", "label": "Cost Related to Prospectus Supplement Amount", "terseLabel": "Cost Related to Prospectus Supplement Amount" } } }, "localname": "CostRelatedToProspectusSupplementAmount", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "acst_DebtInstrumentTranslationEffect": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents information related to translation effect for debt instrument.", "label": "Translation effect" } } }, "localname": "DebtInstrumentTranslationEffect", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-liability-and-equity-components-details" ], "xbrltype": "monetaryItemType" }, "acst_DeferredFinancingCostsReclassifiedToEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of deferred financing costs reclassified to equity.", "label": "Deferred financing costs reclassified to Equity", "terseLabel": "Deferred financing costs reclassified to Equity" } } }, "localname": "DeferredFinancingCostsReclassifiedToEquity", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-noncash-transactions-details" ], "xbrltype": "monetaryItemType" }, "acst_DeferredTaxAssetsFinancingExpenses": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to financing expenses.", "label": "Financing expenses", "terseLabel": "Financing expenses" } } }, "localname": "DeferredTaxAssetsFinancingExpenses", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "acst_DeferredTaxAssetsResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to research and development expenses.", "label": "Research and development expenses", "terseLabel": "Research and development expenses" } } }, "localname": "DeferredTaxAssetsResearchAndDevelopmentExpenses", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "acst_DeferredTaxLiabilityConvertibleDebtEquityComponent": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from convertible debt equity component.", "label": "acst_DeferredTaxLiabilityConvertibleDebtEquityComponent", "negatedLabel": "Tax basis of unsecured convertible debentures in excess of carrying value" } } }, "localname": "DeferredTaxLiabilityConvertibleDebtEquityComponent", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "acst_DerivativeLiability5PercentDecreaseInVolatilityLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of loss that would be recognized if there is a 5% decrease in the volatility used in measuring fair value of derivative liability.", "label": "acst_DerivativeLiability5PercentDecreaseInVolatilityLoss", "terseLabel": "Derivative Liability, 5 Percent Decrease in Volatility, Loss" } } }, "localname": "DerivativeLiability5PercentDecreaseInVolatilityLoss", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "acst_DerivativeLiability5PercentIncreaseCurrencyGain": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of gain that would be recognized on derivative liability if the currency strengthened by 5%.", "label": "acst_DerivativeLiability5PercentIncreaseCurrencyGain", "terseLabel": "Derivative Liability, 5 Percent Increase Currency, Gain" } } }, "localname": "DerivativeLiability5PercentIncreaseCurrencyGain", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "acst_DerivativeLiability5PercentIncreaseInVolatilityGain": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of gain that would be recognized if there is a 5% increase in the volatility used in measuring fair value of derivative liability.", "label": "acst_DerivativeLiability5PercentIncreaseInVolatilityGain", "terseLabel": "Derivative Liability, 5 Percent Increase in Volatility, Gain" } } }, "localname": "DerivativeLiability5PercentIncreaseInVolatilityGain", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "acst_DerivativeLiabilityWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents derivative liability warrants.", "label": "Derivative Liability Warrants [Member]", "terseLabel": "Derivative Liability Warrants [Member]" } } }, "localname": "DerivativeLiabilityWarrantsMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-warrants-details" ], "xbrltype": "domainItemType" }, "acst_DirectorsAndEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents directors and employees.", "label": "Directors and Employees [Member]" } } }, "localname": "DirectorsAndEmployeesMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "domainItemType" }, "acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Of the amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, this element represents the accumulated depreciation component.", "label": "acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation", "negatedLabel": "Equipment held-for-sale, accumulated depreciation" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "acst_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Of the amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, this element represents the cost component.", "label": "Equipment held-for-sale, cost", "terseLabel": "Equipment held-for-sale, cost" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "acst_EffectOfTranslationEffectOnCashAndCashEquivalents": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of exchange rate fluctuations on cash and cash equivalents", "terseLabel": "Effect of exchange rate fluctuations on cash and cash equivalents" } } }, "localname": "EffectOfTranslationEffectOnCashAndCashEquivalents", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "acst_EffectiveIncomeTaxRateReconciliationForeignExchangeAmount": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign exchange.", "label": "Other \u2013 Foreign exchange", "terseLabel": "Other -Foreign exchange" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignExchangeAmount", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "acst_EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the equity incentive plan.", "label": "Equity Incentive Plan [Member]", "terseLabel": "Equity Incentive Plan [Member]" } } }, "localname": "EquityIncentivePlanMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "acst_ExercisePriceRange1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents exercise price range one.", "label": "Exercise Price Range 1 [Member]", "terseLabel": "Exercise Price Range 1 [Member]" } } }, "localname": "ExercisePriceRange1Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "domainItemType" }, "acst_ExercisePriceRange2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents exercise price range two.", "label": "Exercise Price Range 2 [Member]", "terseLabel": "Exercise Price Range 2 [Member]" } } }, "localname": "ExercisePriceRange2Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "domainItemType" }, "acst_ExercisePriceRange3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents exercise price range 3.", "label": "Exercise Price Range 3 [Member]", "terseLabel": "Exercise Price Range 3 [Member]" } } }, "localname": "ExercisePriceRange3Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "domainItemType" }, "acst_ExercisePriceRange4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents exercise price range four.", "label": "Exercise Price Range 4 [Member]", "terseLabel": "Exercise Price Range 4 [Member]" } } }, "localname": "ExercisePriceRange4Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "domainItemType" }, "acst_ExercisePriceRange5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents exercise price range 5.", "label": "Exercise Price Range 5 [Member]", "terseLabel": "Exercise Price Range 5 [Member]" } } }, "localname": "ExercisePriceRange5Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "domainItemType" }, "acst_ExercisePriceRange6Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents exercise price range six.", "label": "Exercise Price Range 6 [Member]", "terseLabel": "Exercise Price Range 6 [Member]" } } }, "localname": "ExercisePriceRange6Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "domainItemType" }, "acst_ExercisePriceRange7Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents exercise price range seven.", "label": "Exercise Price Range 7 [Member]", "terseLabel": "Exercise Price Range 7 [Member]" } } }, "localname": "ExercisePriceRange7Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "domainItemType" }, "acst_ExercisePriceRange8Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents exercise price range eight.", "label": "Exercise Price Range 8 [Member]", "terseLabel": "Exercise Price Range 8 [Member]" } } }, "localname": "ExercisePriceRange8Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "domainItemType" }, "acst_ExercisePriceRange9Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents exercise price range nine.", "label": "Exercise Price Range 9 [Member]", "terseLabel": "Exercise Price Range 9 [Member]" } } }, "localname": "ExercisePriceRange9Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "domainItemType" }, "acst_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) due to foreign currency transactions on liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "acst_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyGainLoss", "terseLabel": "Translation effect" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyGainLoss", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesChangesInFairValueDetails" ], "xbrltype": "monetaryItemType" }, "acst_FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The fair value of derivative warrants liability that reclassified to equity.", "label": "Fair value of derivative warrants liability reclassified to equity", "terseLabel": "Fair value of derivative warrants liability reclassified to equity" } } }, "localname": "FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-noncash-transactions-details" ], "xbrltype": "monetaryItemType" }, "acst_FurnitureAndOfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information regarding furniture and office equipment.", "label": "Furniture and Office Equipment [Member]", "terseLabel": "Furniture and Office Equipment [Member]" } } }, "localname": "FurnitureAndOfficeEquipmentMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "xbrltype": "domainItemType" }, "acst_GovernmentAssistance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of government assistance recorded in earnings.", "label": "acst_GovernmentAssistance", "terseLabel": "Government Assistance" } } }, "localname": "GovernmentAssistance", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceDetailsTextual" ], "xbrltype": "monetaryItemType" }, "acst_GovernmentAssistanceTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for government assistance.", "label": "Government Assistance [Text Block]", "terseLabel": "Government Assistance" } } }, "localname": "GovernmentAssistanceTextBlock", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistance1" ], "xbrltype": "textBlockItemType" }, "acst_GovernmentGrantsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The accounting policy for government grants.", "label": "Government Grants [Policy Text Block]", "terseLabel": "Government grants" } } }, "localname": "GovernmentGrantsPolicyTextBlock", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "acst_GraceTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Grace Therapeutics Inc.", "label": "Grace Therapeutics Inc. [Member]", "terseLabel": "Grace Therapeutics Inc Member" } } }, "localname": "GraceTherapeuticsIncMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" ], "xbrltype": "domainItemType" }, "acst_GrantsAndInvestmentTaxCreditReceivable": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote5ReceivablesReceivablesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants and investment tax credits.", "label": "Government assistance", "terseLabel": "Government assistance", "totalLabel": "Total government assistance" } } }, "localname": "GrantsAndInvestmentTaxCreditReceivable", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote5ReceivablesReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "acst_Gtx101Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GTX 101.", "label": "GTX 101 [Member]", "terseLabel": "GTX 101 [Member]" } } }, "localname": "Gtx101Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" ], "xbrltype": "domainItemType" }, "acst_Gtx102Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GTX 102.", "label": "GTX 102 [Member]", "terseLabel": "GTX 102 [Member]" } } }, "localname": "Gtx102Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" ], "xbrltype": "domainItemType" }, "acst_Gtx104Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GTX 104.", "label": "GTX 104 [Member]", "terseLabel": "GTX 104 [Member]" } } }, "localname": "Gtx104Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" ], "xbrltype": "domainItemType" }, "acst_ImpairmentOfOtherAssetsAndPrepaids": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings resulting from the write down of other assets and prepaid.", "label": "Impairment of other assets and prepaids", "negatedLabel": "Impairment of Other assets and prepaid", "terseLabel": "Impairment loss", "verboseLabel": "Impairment of other assets and prepaids" } } }, "localname": "ImpairmentOfOtherAssetsAndPrepaids", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "acst_IncomeTaxReconciliationNondeductibleChangeInFairValue": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible change in fair value.", "label": "Non-deductible change in fair value of warrants", "terseLabel": "Non-deductible change in fair value of warrants" } } }, "localname": "IncomeTaxReconciliationNondeductibleChangeInFairValue", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "acst_IncomeTaxReconciliationNondeductibleExpenseTransactionCosts": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation nondeductible expense transaction costs.", "label": "Income Tax Reconciliation Nondeductible Expense Transaction Costs", "terseLabel": "Non-deductible transaction costs" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseTransactionCosts", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrecognized temporary differences.", "label": "acst_IncomeTaxReconciliationUnrecognizedTemporaryDifferences", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationUnrecognizedTemporaryDifferences", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "acst_IncomeTaxRecoveryExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax (recovery) expense:", "label": "Income tax (recovery) expense [Abstract]" } } }, "localname": "IncomeTaxRecoveryExpenseAbstract", "nsuri": "http://www.acastipharma.com/20220331", "xbrltype": "stringItemType" }, "acst_IncreaseDecreaseInWorkingCapital": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-changes-in-working-capital-items-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of working capital.", "label": "acst_IncreaseDecreaseInWorkingCapital", "negatedLabel": "Changes in non-cash working capital items", "negatedTotalLabel": "Total changes in working capital items" } } }, "localname": "IncreaseDecreaseInWorkingCapital", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-changes-in-working-capital-items-details" ], "xbrltype": "monetaryItemType" }, "acst_InvestmentTaxCreditReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of investment tax credit receivable as of the balance sheet date.", "label": "Investment tax credit", "terseLabel": "Investment tax credit" } } }, "localname": "InvestmentTaxCreditReceivable", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceGovernmentAssistanceDetails" ], "xbrltype": "monetaryItemType" }, "acst_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment [Member]" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details" ], "xbrltype": "domainItemType" }, "acst_Licenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Licenses", "label": "Licenses" } } }, "localname": "Licenses", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "acst_NoExpiryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No Expiry [Member]", "label": "No Expiry [Member]", "terseLabel": "No Expiry [Member]" } } }, "localname": "NoExpiryMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_NonRefundableFederalItc": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-refundable Federal ITC", "label": "Non-refundable Federal ITC", "negatedLabel": "Non-refundable Federal ITC" } } }, "localname": "NonRefundableFederalItc", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "acst_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.acastipharma.com/20220331", "xbrltype": "stringItemType" }, "acst_OppenheimerAndCoIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Oppenheimer and Co. Inc.", "label": "Oppenheimer & Co. Inc. [Member]" } } }, "localname": "OppenheimerAndCoIncMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "domainItemType" }, "acst_OtherTaxCreditCarryforwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax credit carryforwards that are classified as other.", "label": "Other Tax Credit Carryforward [Member]" } } }, "localname": "OtherTaxCreditCarryforwardMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_OverallotmentOptionWarrantsIssuedDecember2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents over-allotment option warrants issued December 2017.", "label": "Over-Allotment Option Warrants Issued December 2017 [Member]", "terseLabel": "Over-Allotment Option Warrants Issued December 2017 [Member]" } } }, "localname": "OverallotmentOptionWarrantsIssuedDecember2017Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual" ], "xbrltype": "domainItemType" }, "acst_OverallotmentOptionWarrantsIssuedInMay2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents over-allotment option warrants issued in May 2018.", "label": "Over-Allotment Option Warrants Issued in May 2018 [Member]", "terseLabel": "Over-Allotment Option Warrants Issued in May 2018 [Member]" } } }, "localname": "OverallotmentOptionWarrantsIssuedInMay2018Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-warrants-details" ], "xbrltype": "domainItemType" }, "acst_PaymentsForInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow for interest.", "label": "acst_PaymentsForInterest", "negatedLabel": "Accretion of interest on convertible debenture" } } }, "localname": "PaymentsForInterest", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-liability-and-equity-components-details" ], "xbrltype": "monetaryItemType" }, "acst_PaymentsForProceedsFromFinancingCosts": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash outflow or inflow for loan and debt issuance costs.", "label": "acst_PaymentsForProceedsFromFinancingCosts", "negatedLabel": "Deferred financing costs", "terseLabel": "Deferred financing costs" } } }, "localname": "PaymentsForProceedsFromFinancingCosts", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "acst_ProceedsFromIssuanceOfCommonStockGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common Stock gross", "label": "Proceeds From Issuance of Common Stock Gross", "terseLabel": "Proceeds From Issuance of Common Stock, Gross" } } }, "localname": "ProceedsFromIssuanceOfCommonStockGross", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/Disclosure21SubsequentEventsAdditionalInformationDetailsTextual" ], "xbrltype": "monetaryItemType" }, "acst_ProceedsFromIssuanceOfCommonStockNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, net of issuance cost.", "label": "acst_ProceedsFromIssuanceOfCommonStockNet", "terseLabel": "Proceeds from Issuance of Common Stock, Net" } } }, "localname": "ProceedsFromIssuanceOfCommonStockNet", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/Disclosure21SubsequentEventsAdditionalInformationDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "acst_ProceedsFromNRCIRAP": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the National Research Council of Canada Industrial Research Assistance Program.", "label": "acst_ProceedsFromNRCIRAP", "terseLabel": "Proceeds from NRC IRAP" } } }, "localname": "ProceedsFromNRCIRAP", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceDetailsTextual" ], "xbrltype": "monetaryItemType" }, "acst_ProductionEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents production equipment.", "label": "Production Equipment [Member]", "terseLabel": "Production Equipment [Member]" } } }, "localname": "ProductionEquipmentMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details" ], "xbrltype": "domainItemType" }, "acst_PropertyPantAndEquipmentDepreciationRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The depreciation rate of property, plant and equipment.", "label": "Rate", "terseLabel": "Rate" } } }, "localname": "PropertyPantAndEquipmentDepreciationRate", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details" ], "xbrltype": "percentItemType" }, "acst_PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for useful lives and rates for property, plant and equipment.", "label": "Property, Plant and Equipment, Useful Lives and Rates [Table Text Block]", "terseLabel": "Property, Plant and Equipment, Useful Lives and Rates" } } }, "localname": "PropertyPlantAndEquipmentUsefulLivesAndRatesTableTextBlock", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "acst_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents public offering.", "label": "Public Offering [Member]", "terseLabel": "Public Offering [Member]" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual" ], "xbrltype": "domainItemType" }, "acst_RKOSupplyAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the RKO Supply Agreement.", "label": "RKO Supply Agreement [Member]", "terseLabel": "RKO Supply Agreement [Member]" } } }, "localname": "RKOSupplyAgreementMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "domainItemType" }, "acst_RelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents related party.", "label": "Related Party [Member]", "terseLabel": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual" ], "xbrltype": "domainItemType" }, "acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of incentive to be paid if individual continues employment until the earlier of April 30, 2021 or the closing of a merger or similar transaction with third party under the retention incentive agreement.", "label": "acst_RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty", "terseLabel": "Retention Incentive Agreement, Continued Employment Until April 30, 2021 or Closing Transaction With Third Party" } } }, "localname": "RetentionAgreementIncentiveContinuedEmploymentUntilApril302021OrClosingTransactionWithThirdParty", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "acst_RetentionIncentiveAgreementMaximumConditionalIncentives": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum amount of incentives that can be paid upon certain conditions being met under the retention incentive agreement.", "label": "acst_RetentionIncentiveAgreementMaximumConditionalIncentives", "terseLabel": "Retention Incentive Agreement, Maximum Conditional Incentives" } } }, "localname": "RetentionIncentiveAgreementMaximumConditionalIncentives", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "acst_ReverseStockSplitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to reverse stock split.", "label": "Reverse Stock Split [Member]", "terseLabel": "Reverse Stock Split [Member]" } } }, "localname": "ReverseStockSplitMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual" ], "xbrltype": "domainItemType" }, "acst_SaleOfStockAveragePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The average price per share received by entity for each share of common stock issued or sold in the stock transaction.", "label": "acst_SaleOfStockAveragePricePerShare", "terseLabel": "Sale of Stock, Average Price Per Share (in dollars per share)" } } }, "localname": "SaleOfStockAveragePricePerShare", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "perShareItemType" }, "acst_SalesTaxReceivablesCurrent": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote5ReceivablesReceivablesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of sales taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Sales tax receivables", "terseLabel": "Sales tax receivables" } } }, "localname": "SalesTaxReceivablesCurrent", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote5ReceivablesReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "acst_ScheduleOfGovernmentAssistanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for government assistance.", "label": "Schedule of Government Assistance [Table Text Block]", "terseLabel": "Schedule of Government Assistance" } } }, "localname": "ScheduleOfGovernmentAssistanceTableTextBlock", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceTables" ], "xbrltype": "textBlockItemType" }, "acst_ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for useful life of intangible assets.", "label": "Schedule of Intangible Assets, Useful Life [Table Text Block]", "terseLabel": "Schedule of Intangible Assets, Useful Life" } } }, "localname": "ScheduleOfIntangibleAssetsUsefulLifeTableTextBlock", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "acst_ScheduleOfNonvestedOptionActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for nonvested option activity.", "label": "Schedule of Nonvested Option Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Option Activity" } } }, "localname": "ScheduleOfNonvestedOptionActivityTableTextBlock", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-tables" ], "xbrltype": "textBlockItemType" }, "acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued to one person in accordance with the plan as a proportion of outstanding capital stock.", "label": "acst_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Per Person" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumPerPerson", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual" ], "xbrltype": "percentItemType" }, "acst_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted-average fair value price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Exercisable, weighted average fair value (in CAD per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "perShareItemType" }, "acst_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value of options exercised during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Exercised, weighted average fair value (in CAD per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "perShareItemType" }, "acst_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options expired during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Expired, weighted average fair value (in CAD per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "perShareItemType" }, "acst_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value of options forfeited during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Forfeited, weighted average fair value (in CAD per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageFairValue", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "perShareItemType" }, "acst_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value of options outstanding during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "acst_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageFairValue", "periodEndLabel": "Outstanding, weighted average fair value (in CAD per share)", "periodStartLabel": "Outstanding, weighted average fair value (in CAD per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageFairValue", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "perShareItemType" }, "acst_SherbrookLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sherbrook Lease [Member]", "label": "Sherbrook Lease [Member]", "terseLabel": "Sherbrook Lease" } } }, "localname": "SherbrookLeaseMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "domainItemType" }, "acst_StockIssuedDuringPeriodSharesWarrantExcercises": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for warrants exercised during the current period.", "label": "Warrants exercised (in shares)", "terseLabel": "Warrants exercised (in shares)", "verboseLabel": "Stock Issued During Period, Shares, Warrant Excercises (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantExcercises", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "sharesItemType" }, "acst_StockIssuedDuringPeriodValueWarrantExercises": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock issued for warrants exercised during the period.", "label": "Warrants exercised", "terseLabel": "Warrants exercised" } } }, "localname": "StockIssuedDuringPeriodValueWarrantExercises", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "acst_StockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the stock option plan.", "label": "Stock Option Plan [Member]", "terseLabel": "Stock Option Plan [Member]" } } }, "localname": "StockOptionPlanMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-compensation-expense-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "domainItemType" }, "acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the success fees to be paid by the corporation based on the outcome of the strategic evaluation.", "label": "acst_SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation", "terseLabel": "Success Fees to be Paid Based on the Outcome of the Strategic Evaluation" } } }, "localname": "SuccessFeesToBePaidBasedOnTheOutcomeOfTheStrategicEvaluation", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "acst_TaxCreditCarryForwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the tax credit carry forwards.", "label": "Tax Credit Carry Forwards [Member]" } } }, "localname": "TaxCreditCarryForwardsMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TaxCreditCarryforwardNotSubjectToTimeLimitation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws, not subject to time limitation.", "label": "Carryforwards, without time limitation" } } }, "localname": "TaxCreditCarryforwardNotSubjectToTimeLimitation", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "monetaryItemType" }, "acst_TaxYear2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2028.", "label": "Tax Year 2028 [Member]" } } }, "localname": "TaxYear2028Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TaxYear2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2029.", "label": "Tax Year 2029 [Member]" } } }, "localname": "TaxYear2029Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TaxYear2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2030.", "label": "Tax Year 2030 [Member]" } } }, "localname": "TaxYear2030Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TaxYear2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2031.", "label": "Tax Year 2031 [Member]" } } }, "localname": "TaxYear2031Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TaxYear2032Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2032.", "label": "Tax Year 2032 [Member]" } } }, "localname": "TaxYear2032Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TaxYear2033Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2033.", "label": "Tax Year 2033 [Member]" } } }, "localname": "TaxYear2033Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TaxYear2034Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2034.", "label": "Tax Year 2034 [Member]" } } }, "localname": "TaxYear2034Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TaxYear2035Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2035.", "label": "Tax Year 2035 [Member]" } } }, "localname": "TaxYear2035Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TaxYear2036Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2036.", "label": "Tax Year 2036 [Member]" } } }, "localname": "TaxYear2036Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TaxYear2037Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2037.", "label": "Tax Year 2037 [Member]" } } }, "localname": "TaxYear2037Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TaxYear2038Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2038.", "label": "Tax Year 2038 [Member]" } } }, "localname": "TaxYear2038Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TaxYear2039Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2039.", "label": "Tax Year 2039 [Member]" } } }, "localname": "TaxYear2039Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TaxYear2040Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2040.", "label": "Tax Year 2040 [Member]" } } }, "localname": "TaxYear2040Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TaxYear2041Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to 2041.", "label": "Tax Year 2041 [Member]" } } }, "localname": "TaxYear2041Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TaxYear2042Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax year 2042 member", "label": "Tax Year 2042 [Member]", "terseLabel": "Tax Year 2042 [Member]" } } }, "localname": "TaxYear2042Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "acst_TransactionCostsRelatedToDerivativeWarrantLiability": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialExpensesFinancialIncomeExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction costs related to derivative warrant liability.", "label": "acst_TransactionCostsRelatedToDerivativeWarrantLiability", "negatedTotalLabel": "Financial income (expenses)" } } }, "localname": "TransactionCostsRelatedToDerivativeWarrantLiability", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialExpensesFinancialIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "acst_UnrecognizedCompensationCostRelatedToNonVestedShareOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrecognized compensation cost related to non-vested share options", "label": "Unrecognized compensation cost related to non-vested share options", "terseLabel": "Unrecognized compensation cost, related to non-vested share options" } } }, "localname": "UnrecognizedCompensationCostRelatedToNonVestedShareOptions", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "acst_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in unrecognized tax benefits resulting from change in valuation allowance.", "label": "Change in valuation allowance", "terseLabel": "Change in valuation allowance" } } }, "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromChangeInValuationAllowance", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "acst_UnsecuredConvertibleDebenturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents unsecured convertible debentures.", "label": "Unsecured Convertible Debentures [Member]" } } }, "localname": "UnsecuredConvertibleDebenturesMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-liability-and-equity-components-details" ], "xbrltype": "domainItemType" }, "acst_WarrantsAndRightsFairValuePerShareIssuable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fair value amount per share of issuable warrants and rights.", "label": "Fair value per warrant issuable (in dollars per share)" } } }, "localname": "WarrantsAndRightsFairValuePerShareIssuable", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesChangesInFairValueDetails" ], "xbrltype": "perShareItemType" }, "acst_WarrantsIssuedDecember272017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrants issued December 27, 2017.", "label": "Warrants Issued December 27, 2017 [Member]", "terseLabel": "Warrants Issued December 2017 [Member]" } } }, "localname": "WarrantsIssuedDecember272017Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesAssumptionsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesChangesInFairValueDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-warrants-details" ], "xbrltype": "domainItemType" }, "acst_WarrantsIssuedInConnectionWithPrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrants issued in connection with private placement.", "label": "Warrants Issued in Connection with Private Placement [Member]" } } }, "localname": "WarrantsIssuedInConnectionWithPrivatePlacementMember", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-details-textual" ], "xbrltype": "domainItemType" }, "acst_WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrants issued in connection with the public offering in February 2017.", "label": "Warrants Issued in Connection with Public Offering February 2017 [Member]", "terseLabel": "Warrants Issued in Connection with Public Offering February 2017 [Member]" } } }, "localname": "WarrantsIssuedInConnectionWithPublicOfferingFebruary2017Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-warrants-details" ], "xbrltype": "domainItemType" }, "acst_WarrantsIssuedInMay2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrants issued in May 2018.", "label": "Warrants Issued in May 2018 [Member]", "terseLabel": "Warrants Issued in May 2018 [Member]" } } }, "localname": "WarrantsIssuedInMay2018Member", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesAssumptionsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesChangesInFairValueDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "domainItemType" }, "acst_WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount recognized during the period for the write off of deferred financing costs of at-the-market (ATM) program.", "label": "Write off-of deferred financing costs of at-the-market (ATM) program", "negatedLabel": "Write-off of deferred financing fees related to at-the-market (ATM) program", "terseLabel": "Write Off of Deferred Financing Costs of At-the-Market Program", "verboseLabel": "Write off-of deferred financing costs of at-the-market (ATM) program" } } }, "localname": "WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram", "nsuri": "http://www.acastipharma.com/20220331", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "country_FR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FRANCE", "terseLabel": "FRANCE" } } }, "localname": "FR", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States [Member]" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding (in shares)", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "trueItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r606" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r64", "r66", "r110", "r111", "r276", "r299" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r275", "r298", "r338", "r340", "r505", "r506", "r507", "r508", "r509", "r510", "r529", "r572", "r574", "r600", "r601" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetailsParentheticals", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r275", "r298", "r338", "r340", "r505", "r506", "r507", "r508", "r509", "r510", "r529", "r572", "r574", "r600", "r601" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetailsParentheticals", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r275", "r298", "r336", "r338", "r340", "r505", "r506", "r507", "r508", "r509", "r510", "r529", "r572", "r574", "r600", "r601" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetailsParentheticals", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r275", "r298", "r336", "r338", "r340", "r505", "r506", "r507", "r508", "r509", "r510", "r529", "r572", "r574", "r600", "r601" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetailsParentheticals", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r65", "r66", "r110", "r111", "r276", "r299" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r180", "r181", "r327", "r329", "r573", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r180", "r181", "r327", "r329", "r573", "r587", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r183", "r492" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote10TradeAndOtherPayablesTradeAndOtherPayablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Trade and other payables", "terseLabel": "Trade and other payables", "totalLabel": "Total trade and other payables" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote10TradeAndOtherPayablesTradeAndOtherPayablesDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Trade and Other Payables" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote10TradeAndOtherPayables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r24", "r50" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote10TradeAndOtherPayablesTradeAndOtherPayablesDetails": { "order": 0.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Trade payables", "terseLabel": "Trade payables" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote10TradeAndOtherPayablesTradeAndOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r18", "r36", "r184", "r185" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote5ReceivablesReceivablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "us-gaap_AccountsReceivableNetCurrent", "totalLabel": "Total receivables" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote5ReceivablesReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote10TradeAndOtherPayablesTradeAndOtherPayablesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities and other payables", "terseLabel": "Accrued liabilities and other payables", "totalLabel": "Accrued Liabilities, Current, Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote10TradeAndOtherPayablesTradeAndOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r39", "r69", "r70", "r71", "r561", "r579", "r582" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r68", "r71", "r75", "r76", "r77", "r114", "r115", "r116", "r443", "r575", "r576", "r621" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r37", "r378", "r495" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital", "periodEndLabel": "Additional Paid in Capital, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "terseLabel": "Additional paid-in capital", "totalLabel": "Additional Paid in Capital, Total" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r114", "r115", "r116", "r374", "r375", "r376", "r453" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r312", "r314" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "terseLabel": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments:", "terseLabel": "Adjustments:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r342", "r370", "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-compensation-expense-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r93", "r223", "r231" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of intangible assets", "terseLabel": "Amortization of Intangible Assets", "totalLabel": "Amortization of Intangible Assets, Total", "verboseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote7ImpairmentLossIntangibleAssetsDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r93", "r238" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "us-gaap_AssetImpairmentCharges", "terseLabel": "Asset Impairment Charges, Total", "totalLabel": "Asset Impairment Charges, Total" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r106", "r162", "r171", "r177", "r204", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r441", "r444", "r465", "r493", "r495", "r540", "r558" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "terseLabel": "Assets, Total", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets [Abstract]" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r21", "r23", "r62", "r106", "r204", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r441", "r444", "r465", "r493", "r495" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Held-for-sale, Not Part of Disposal Group [Abstract]" } } }, "localname": "AssetsHeldForSaleNotPartOfDisposalGroupAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r2", "r3", "r10", "r12", "r15", "r239", "r245" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Assets held for sale", "terseLabel": "Assets held for sale", "totalLabel": "Disposal Group, Including Discontinued Operation, Assets, Current, Total" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r344", "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-assumptions-details" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r337", "r339" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r337", "r339", "r430", "r431" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Total common shares issued (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r428", "r429" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Business Acquisition, Pro Forma Information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Acasti share price (closing share price on August 27, 2021)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r428", "r429" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net loss" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceProFormaFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Business Combination, Acquisition Related Costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r437", "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Fair value of common shares issued" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisition of Grace" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGrace" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r433" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r433" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r433" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedLabel": "Deferred tax liability", "terseLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r432", "r433" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Intangible assets in process research and development" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r432", "r433" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total assets acquired and liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r44", "r495", "r583", "r584" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "us-gaap_Cash", "periodEndLabel": "Cash", "periodStartLabel": "Cash, Beginning Balance", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents are comprised of:" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r17", "r44", "r95" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r25", "r96" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents:" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r90", "r95", "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents, end of year", "periodStartLabel": "Cash and cash equivalents, beginning of year", "terseLabel": "Cash and cash equivalents, beginning of year", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r90", "r471" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r44" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "us-gaap_CashEquivalentsAtCarryingValue", "periodEndLabel": "Cash equivalents", "terseLabel": "Cash equivalents", "totalLabel": "Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingCapitalTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the net increase (decrease) in operating capital in the operating section of the statement of cash flows, represents the entire footnote disclosure that provides details regarding the net change during the reporting period of all assets and liabilities used in operating activities.", "label": "Cash Flow, Operating Capital [Table Text Block]", "terseLabel": "Schedule of Changes in working capital items" } } }, "localname": "CashFlowOperatingCapitalTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Supplemental cash flow disclosure" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r104", "r106", "r133", "r134", "r135", "r137", "r139", "r145", "r146", "r147", "r204", "r263", "r267", "r268", "r269", "r272", "r273", "r296", "r297", "r301", "r305", "r465", "r611" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r316", "r341" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesAssumptionsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-warrants-details" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesAssumptionsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in CAD per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "terseLabel": "Class of Warrant or Right, Outstanding (in shares)", "verboseLabel": "Number outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-warrants-details" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r58", "r260", "r547", "r566" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r257", "r258", "r259", "r261", "r588" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation.", "label": "Common Class C [Member]", "terseLabel": "Common Class C [Member]" } } }, "localname": "CommonClassCMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r114", "r115", "r453" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "us-gaap_CommonStockSharesIssued", "terseLabel": "Common Stock, Shares, Issued, Total (in shares)", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r35", "r312" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "us-gaap_CommonStockSharesOutstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common Stock, Shares, Outstanding, Ending Balance (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r35", "r495" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common shares", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common shares", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "auth_ref": [ "r97", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "Information by description of stock conversions.", "label": "Stock Conversion Description [Axis]" } } }, "localname": "ConversionOfStockByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Conversion of Stock [Line Items]" } } }, "localname": "ConversionOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockNameDomain": { "auth_ref": [ "r97", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "The unique name of a noncash or part noncash stock conversion.", "label": "Conversion of Stock, Name [Domain]" } } }, "localname": "ConversionOfStockNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockTable": { "auth_ref": [ "r97", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "This table may be used to disclose all the information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction. It may include a description sufficient information to understand the nature and purpose of the conversion, as well as the financial instruments converted from and to (for example, preferred, common, treasury, etc.) the amounts converted, the new shares issued, and the value of the new shares issued, if applicable. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock [Table]" } } }, "localname": "ConversionOfStockTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r29", "r542", "r559" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "us-gaap_ConvertibleDebt", "periodEndLabel": "Ending balance, total private placement", "periodStartLabel": "Beginning balance, total private placement", "totalLabel": "Convertible Debt, Total" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-liability-and-equity-components-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r81", "r531" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "us-gaap_CostOfGoodsAndServicesSold", "negatedLabel": "Cost of sales of products", "totalLabel": "Cost of Goods and Services Sold, Total" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r408", "r418", "r420" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "terseLabel": "Current tax (recovery) expense", "totalLabel": "Current Income Tax Expense (Benefit), Total" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote18IncomeTaxesIncomeTaxRecoveryExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r97", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "us-gaap_DebtConversionOriginalDebtAmount1", "negatedLabel": "Shares issued upon exercise of warrants" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-liability-and-equity-components-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r103", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r288", "r293" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r29", "r290", "r542", "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "us-gaap_DebtInstrumentCarryingAmount", "periodEndLabel": "Ending balance, liability component", "periodStartLabel": "Beginning balance, liability component" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-liability-and-equity-components-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "periodEndLabel": "Ending balance, equity component", "periodStartLabel": "Beginning balance, equity component" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-liability-and-equity-components-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r274", "r291", "r292", "r480", "r481", "r482" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Deferred Financing Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r93", "r107", "r409", "r418", "r419", "r420" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred tax (recovery) expense", "totalLabel": "Deferred tax (recovery) expense" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote18IncomeTaxesIncomeTaxRecoveryExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r31", "r32", "r398", "r541", "r555" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Deferred tax liabilities", "totalLabel": "Deferred Tax Liabilities, Gross, Total" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r388", "r389" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability", "totalLabel": "Deferred Income Tax Liabilities, Net, Total" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Intangible assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r399" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r401" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r406", "r407" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards", "terseLabel": "Tax losses carried forward", "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r406", "r407" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Other temporary differences", "terseLabel": "Other temporary differences" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Property, plan and equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r404", "r406", "r407" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Tax credit carry forwards", "terseLabel": "Tax credit carry forwards", "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r400" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation allowance", "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsMember": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Amounts held on account by the entity representing a liability to the depositor. Deposits may take various forms (for example, demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits) and may be categorized in multiple ways (such as, foreign and domestic, interest and noninterest bearing).", "label": "Deposits [Member]", "terseLabel": "Deposits [Member]" } } }, "localname": "DepositsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetailsParentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r93", "r240" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation of equipment", "terseLabel": "Depreciation expense", "totalLabel": "Depreciation, Total", "verboseLabel": "Depreciation of equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r451", "r455" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Warrant Liabilities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative warrant liabilities", "terseLabel": "Derivative warrant liabilities" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative warrant liability, measurement input", "terseLabel": "Derivative warrant liability, measurement input" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesAssumptionsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r112", "r446", "r447", "r448", "r449", "r450" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative financial instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-based Payment Arrangement" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r12", "r236", "r246" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]" } } }, "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "auth_ref": [ "r2", "r3", "r10", "r239", "r245" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Other assets", "terseLabel": "Other assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "auth_ref": [ "r2", "r3", "r10", "r245" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.", "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "terseLabel": "Equipment held-for-sale, net book value" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "auth_ref": [ "r2", "r3", "r10", "r239", "r245" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails": { "order": 0.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Equipment", "terseLabel": "Equipment" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r16", "r249" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Assets held for sale" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSale" ], "xbrltype": "textBlockItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Basic and diluted loss per share (in dollars per share)", "terseLabel": "Basic and diluted loss per share (in dollars per share)", "totalLabel": "Earnings Per Share, Basic and Diluted, Total" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r140", "r141" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earning per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r140", "r141", "r142", "r143" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Loss per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-16-loss-per-share" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r471" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Translation effect on cash and cash equivalents related to reporting currency", "terseLabel": "Translation effect on cash and cash equivalents related to reporting currency", "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r108", "r391", "r421" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Basic combined Canadian statutory income tax rate", "terseLabel": "Basic combined Canadian statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote10TradeAndOtherPayablesTradeAndOtherPayablesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee salaries and benefits payable", "terseLabel": "Employee salaries and benefits payable", "totalLabel": "Employee-related Liabilities, Current, Total" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote10TradeAndOtherPayablesTradeAndOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-assumptions-details" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r75", "r76", "r77", "r114", "r115", "r116", "r120", "r127", "r129", "r144", "r205", "r312", "r314", "r374", "r375", "r376", "r411", "r412", "r453", "r472", "r473", "r474", "r475", "r476", "r477", "r575", "r576", "r577", "r621" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r93", "r294" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialExpensesFinancialIncomeExpensesDetails": { "order": 0.0, "parentTag": "acst_TransactionCostsRelatedToDerivativeWarrantLiability", "weight": 1.0 }, "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Change in fair value of warrant liabilities", "negatedLabel": "Change in fair value of warrant liabilities", "terseLabel": "Change in fair value of warrant liabilities" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialExpensesFinancialIncomeExpensesDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesChangesInFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesChangesInFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesChangesInFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r460" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Issued during the year" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesChangesInFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r460" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Amount transferred to Equity" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesChangesInFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r458" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodEndLabel": "Balance \u2013 end of year", "periodStartLabel": "Balance \u2013 beginning of year" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesChangesInFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r463", "r464" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Financial assets and liabilities" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r197", "r198", "r200", "r201", "r202", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r287", "r310", "r451", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r611", "r612", "r613", "r614", "r615", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetailsParentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-19-financial-instruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Patents (Year)", "terseLabel": "Patents (Year)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed.", "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]" } } }, "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r224", "r226", "r230", "r232", "r532", "r536" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r224", "r229" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Increase in finite-lived Intangible Assets", "totalLabel": "Finite-Lived Intangible Assets, Period Increase (Decrease), Total" } } }, "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r225" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Finite-lived Intangible Assets Acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceScheduleOfIntangibleAssetsInProcessResearchAndDevelopmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "auth_ref": [ "r469", "r470" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialExpensesFinancialIncomeExpensesDetails": { "order": 7.0, "parentTag": "acst_TransactionCostsRelatedToDerivativeWarrantLiability", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.", "label": "Foreign exchange gain (loss)", "terseLabel": "Foreign exchange gain (loss)" } } }, "localname": "ForeignCurrencyTransactionGainLossRealized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialExpensesFinancialIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r94", "r469", "r470" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "us-gaap_ForeignCurrencyTransactionGainLossUnrealized", "negatedLabel": "Unrealized foreign exchange loss" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Functional and reporting currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "us-gaap_GeneralAndAdministrativeExpense", "negatedLabel": "General and administrative expenses", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r219", "r220", "r495", "r539" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, Ending Balance", "periodStartLabel": "Goodwill, Beginning Balance", "terseLabel": "Goodwill", "totalLabel": "Goodwill, Total" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Goodwill and Intangible assets impairment", "totalLabel": "Goodwill and Intangible Asset Impairment, Total" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r221", "r227" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible assets - acquired in-process research and development", "verboseLabel": "Goodwill and Intangible assets - acquired in-process research and development" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Increase in goodwill", "totalLabel": "Goodwill, Period Increase (Decrease), Total" } } }, "localname": "GoodwillPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r93", "r233" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of intangible assets", "negatedLabel": "Impairment of Intangible assets", "terseLabel": "Impairment of Intangible Assets, Finite-lived", "verboseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote7ImpairmentLossIntangibleAssetsDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r93", "r238", "r243" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse", "negatedLabel": "Impairment of Equipment", "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r93", "r237" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Equipment", "negatedLabel": "Equipment held-for-sale, impairment loss", "terseLabel": "Impairment of Equipment" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r235", "r248" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In Process Research And Development Member" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual" ], "xbrltype": "domainItemType" }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "auth_ref": [ "r48", "r384" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.", "label": "In Process Research and Development, Policy [Policy Text Block]", "terseLabel": "Schedule of Intangible Assets in Process Research and Development" } } }, "localname": "InProcessResearchAndDevelopmentPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r78", "r162", "r170", "r173", "r176", "r178", "r537", "r549", "r552", "r569" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Loss before income taxes", "terseLabel": "Loss before income taxes", "totalLabel": "Loss before income tax recovery" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r244", "r252" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-compensation-expense-details" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r108", "r392", "r396", "r403", "r416", "r422", "r424", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r109", "r128", "r129", "r161", "r390", "r417", "r423", "r570" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_IncomeTaxExpenseBenefit", "negatedLabel": "Income tax recovery", "negatedTotalLabel": "Income tax (recovery) expense", "terseLabel": "Income tax recovery", "totalLabel": "Income tax (recovery) expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote18IncomeTaxesIncomeTaxRecoveryExpenseDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r74", "r386", "r387", "r396", "r397", "r402", "r410" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income tax" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r391" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "negatedLabel": "Difference in foreign tax rates", "terseLabel": "Difference in foreign tax rates" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r391" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Computed income tax recovery", "terseLabel": "Computed income tax recovery" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r391" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Non-deductible stock-based compensation", "terseLabel": "Non-deductible stock-based compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r391" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Other", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-reconciliation-of-effective-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r92" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-changes-in-working-capital-items-details": { "order": 1.0, "parentTag": "acst_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "negatedLabel": "Trade and other payables", "terseLabel": "Trade and other payables", "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-changes-in-working-capital-items-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r92" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-changes-in-working-capital-items-details": { "order": 0.0, "parentTag": "acst_IncreaseDecreaseInWorkingCapital", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "terseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-changes-in-working-capital-items-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r92" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Increase in deferred tax liability" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r92" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-changes-in-working-capital-items-details": { "order": 2.0, "parentTag": "acst_IncreaseDecreaseInWorkingCapital", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "us-gaap_IncreaseDecreaseInPrepaidExpense", "negatedLabel": "Prepaid expenses", "terseLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-changes-in-working-capital-items-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r92" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-changes-in-working-capital-items-details": { "order": 3.0, "parentTag": "acst_IncreaseDecreaseInWorkingCapital", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInReceivables", "negatedLabel": "Receivables", "terseLabel": "Receivables", "totalLabel": "Increase (Decrease) in Receivables, Total" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-changes-in-working-capital-items-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Impairment Loss Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote7ImpairmentLossIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r222", "r228" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "terseLabel": "Intangible assets", "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableCurrent": { "auth_ref": [ "r61" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote5ReceivablesReceivablesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Interest receivable", "terseLabel": "Interest receivable" } } }, "localname": "InterestReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote5ReceivablesReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCreditMember": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Investment tax credit carryforwards arising from certain qualifying capital expenditures including, but not limited to, rehabilitation, energy, advanced coal project and gasification project.", "label": "Investment Tax Credit Carryforward [Member]" } } }, "localname": "InvestmentCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceTables", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r83", "r160" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialExpensesFinancialIncomeExpensesDetails": { "order": 1.0, "parentTag": "acst_TransactionCostsRelatedToDerivativeWarrantLiability", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialExpensesFinancialIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentInterestRate": { "auth_ref": [ "r195", "r197" ], "lang": { "en-us": { "role": { "documentation": "Rate of interest on investment.", "label": "Investment, interest", "terseLabel": "Investment, interest" } } }, "localname": "InvestmentInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetailsParentheticals" ], "xbrltype": "percentItemType" }, "us-gaap_InvestmentMaturityDate": { "auth_ref": [ "r194", "r196" ], "lang": { "en-us": { "role": { "documentation": "Maturity date of investment, in YYYY-MM-DD format.", "label": "Investment, maturity date", "terseLabel": "Investment, maturity date" } } }, "localname": "InvestmentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetailsParentheticals" ], "xbrltype": "dateItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r203", "r568" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r199", "r538", "r553", "r586", "r618" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Short-term Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r488", "r490" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease agreement commitment amount", "totalLabel": "Lease, Cost, Total" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Additional lease renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r53", "r106", "r172", "r204", "r263", "r264", "r265", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r442", "r444", "r445", "r465", "r493", "r494" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities [Abstract]" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r42", "r106", "r204", "r465", "r495", "r544", "r563" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity [Abstract]" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r56", "r106", "r204", "r263", "r264", "r265", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r442", "r444", "r445", "r465", "r493", "r494", "r495" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "terseLabel": "Liabilities, Current, Total", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "terseLabel": "Receivables" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote5Receivables1" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-liability-and-equity-components-details" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r57", "r262" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-liability-and-equity-components-details" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r548" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Total Investments", "terseLabel": "Total short-term investments", "totalLabel": "Marketable Securities, Total" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r19", "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "us-gaap_MarketableSecuritiesCurrent", "terseLabel": "Short-term investments", "totalLabel": "Marketable Securities, Current, Total" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "us-gaap_MarketableSecuritiesNoncurrent", "terseLabel": "Investments", "totalLabel": "Marketable Securities, Noncurrent, Total" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Table Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]", "terseLabel": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]", "terseLabel": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r148", "r156" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-1-nature-of-operations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r90" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r90" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r90", "r91", "r94" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows used in operating activities:", "terseLabel": "Cash flows used in operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r15", "r72", "r73", "r77", "r79", "r94", "r106", "r119", "r123", "r124", "r125", "r126", "r128", "r129", "r136", "r162", "r170", "r173", "r176", "r178", "r204", "r263", "r264", "r265", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r454", "r465", "r550", "r567" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss and total comprehensive loss for the period", "terseLabel": "Net loss attributable in the consolidated statement of income (loss)", "totalLabel": "Net loss and total comprehensive loss", "verboseLabel": "Net loss for the year" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r1", "r117", "r118", "r121", "r122", "r130", "r131", "r132", "r192", "r193", "r206", "r207", "r330", "r331", "r332", "r333", "r377", "r413", "r414", "r415", "r452", "r466", "r467", "r468", "r491", "r533", "r534", "r535", "r578", "r579", "r580", "r581", "r582", "r622" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-3-recent-accounting-pronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Financial Expenses", "terseLabel": "Financial income (expenses)", "totalLabel": "Nonoperating Income (Expense), Total" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses", "terseLabel": "Operating Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r162", "r170", "r173", "r176", "r178" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operating activities" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r484" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "us-gaap_OperatingLeaseLiabilityCurrent", "terseLabel": "Lease liability", "verboseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r484" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Lease Liability", "terseLabel": "Lease Liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r483" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of Use Asset", "terseLabel": "Right of Use Asset", "verboseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Cumulative translation adjustment", "terseLabel": "Cumulative translation adjustment", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r571" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialExpensesFinancialIncomeExpensesDetails": { "order": 2.0, "parentTag": "acst_TransactionCostsRelatedToDerivativeWarrantLiability", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialExpensesFinancialIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r335", "r382" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Net financial income (expenses)" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialIncomeExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote5ReceivablesReceivablesDetails": { "order": 0.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other receivables", "terseLabel": "Other receivables", "totalLabel": "Other Receivables, Net, Current, Total" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote5ReceivablesReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual" ], "xbrltype": "domainItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents (Year)" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForProceedsFromProductiveAssets": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles.", "label": "us-gaap_PaymentsForProceedsFromProductiveAssets", "negatedLabel": "Acquisition of equipment", "totalLabel": "Payments for (Proceeds from) Productive Assets, Total" } } }, "localname": "PaymentsForProceedsFromProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r87" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "us-gaap_PaymentsToAcquireShortTermInvestments", "negatedLabel": "Acquisition of short-term investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r344", "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-compensation-expense-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-compensation-expense-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r20", "r22", "r217", "r218" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses", "terseLabel": "Prepaid expenses", "totalLabel": "Prepaid Expense, Current, Total" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r88" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Net proceeds from shares issued under the at-the-market (ATM) program", "terseLabel": "Net proceeds from shares issued under the at-the-market (ATM) program" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "auth_ref": [ "r86", "r87" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Maturity of short-term investments", "terseLabel": "Maturity of short-term investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r88", "r373" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of stock options", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r88" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants", "terseLabel": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r47", "r242" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r26", "r27", "r242", "r495", "r554", "r565" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "negatedLabel": "Property, plan and equipment and intangible assets", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property, plan and equipment and intangible assets", "totalLabel": "Property, Plant and Equipment, Net, Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r46", "r242", "r589", "r590" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r26", "r241" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "auth_ref": [ "r30", "r543", "r560" ], "lang": { "en-us": { "role": { "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.", "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "auth_ref": [ "r30", "r543", "r560" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.", "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "auth_ref": [ "r30", "r543", "r560" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.", "label": "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted", "terseLabel": "Purchase Commitment, Remaining Minimum Amount Committed" } } }, "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "us-gaap_PurchaseObligation", "terseLabel": "Purchase Obligation, Total", "totalLabel": "Purchase Obligation, Total" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r36", "r43", "r495", "r564", "r585" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables", "terseLabel": "Receivables", "totalLabel": "Receivables, Net, Current, Total" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r186", "r189", "r190", "r191" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Receivables" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "us-gaap_RepaymentsOfConvertibleDebt", "negatedLabel": "Payment upon maturity of debentures", "negatedTerseLabel": "Payment of convertible debenture" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-liability-and-equity-components-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r383", "r530", "r602" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "us-gaap_ResearchAndDevelopmentExpense", "negatedLabel": "Research and development expenses, net of government assistance", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r38", "r314", "r378", "r495", "r562", "r578", "r582" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r114", "r115", "r116", "r120", "r127", "r129", "r205", "r374", "r375", "r376", "r411", "r412", "r453", "r575", "r577" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r158", "r159", "r169", "r174", "r175", "r179", "r180", "r182", "r326", "r327", "r531" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenues from product sales", "terseLabel": "Revenues from product sales" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r328", "r334" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-13-revenues" ], "xbrltype": "textBlockItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/Disclosure21SubsequentEventsAdditionalInformationDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote5ReceivablesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote10TradeAndOtherPayablesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Non-cash transactions" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-17-supplemental-cash-flow-disclosure-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Income tax (recovery) expense" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]", "terseLabel": "Schedule of Derivative Liabilities at Fair Value" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r3", "r4", "r5", "r6", "r7", "r8", "r9", "r11", "r13", "r14", "r15", "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Disposal Groups, Including Discontinued Operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r342", "r369", "r380" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of Other Nonoperating Income (Expense" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r250", "r251", "r252", "r253", "r254", "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceConsiderationDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote4AcquisitionOfGraceDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r349", "r358", "r360" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Option, Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r316", "r341" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of Stockholders' Equity Note, Warrants or Rights" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r163", "r164", "r165", "r166", "r167", "r168", "r180" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "us-gaap_SellingAndMarketingExpense", "negatedLabel": "Sales and marketing", "totalLabel": "Selling and Marketing Expense, Total" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Selling and Marketing Expense [Member]" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r92" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation expense", "terseLabel": "Stock-based compensation expense", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "terseLabel": "Exercise price (in CAD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-assumptions-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "terseLabel": "Dividend" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "terseLabel": "Risk-free interest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r350", "r352" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance", "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Beginning Balance", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Exercisable, weighted average exercise price (in CAD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "negatedLabel": "Expired, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted, number of options (in shares)", "terseLabel": "Options granted, Number of options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote15StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Granted, weighted average fair value (in CAD per share)", "terseLabel": "Options granted, Weighted average grant date fair value (in CAD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote15StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r351", "r372" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Outstanding, number of options (in shares)", "periodStartLabel": "Outstanding, number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Outstanding, weighted average exercise price (in CAD per share)", "periodStartLabel": "Outstanding, weighted average exercise price (in CAD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r341", "r347" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-assumptions-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted average exercise price (in CAD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Expired, weighted average exercise price (in CAD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited, weighted average exercise price (in CAD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted average exercise price (in CAD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r344", "r348" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Lower limit, exercise price (in CAD per share)", "terseLabel": "Lower limit, exercise price (in CAD per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Number of options exercisable (in shares)", "periodEndLabel": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable, Ending Balance", "periodStartLabel": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable, Beginning Balance", "terseLabel": "Number of options exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Number of options outstanding (in shares)", "periodEndLabel": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Ending Balance", "periodStartLabel": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Beginning Balance", "terseLabel": "Number of options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Upper limit, exercise price (in CAD per share)", "terseLabel": "Upper limit, exercise price (in CAD per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "us-gaap_SharePrice", "terseLabel": "Share price (in CAD per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-assumptions-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r364", "r379" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "terseLabel": "Estimated life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-assumptions-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Number of options Outstanding, Non - vested", "periodStartLabel": "Number of options Outstanding, Non - vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote15StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options forfeited.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "negatedLabel": "Options forfeited and cancelled, Number of options", "terseLabel": "Options forfeited and cancelled, Number of options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote15StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "terseLabel": "Options forfeited and cancelled, Weighted average grant date fair value (in CAD per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote15StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, Weighted average grant date fair value (in CAD per share)", "periodStartLabel": "Outstanding, Weighted average grant date fair value (in CAD per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote15StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Options vested, Number of options", "terseLabel": "Options vested, Number of options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote15StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Options vested, Weighted average grant date fair value (in CAD per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote15StockbasedCompensationSummaryOfTheNonvestedStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual life (Year)", "terseLabel": "Weighted average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r28", "r545", "r546", "r557" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short- term investments", "terseLabel": "Short- term investments", "totalLabel": "Short-term Investments, Total" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Short-term Investments [Abstract]" } } }, "localname": "ShortTermInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShortTermLeaseCommitmentAmount": { "auth_ref": [ "r489" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease commitment.", "label": "Short-term Lease Commitment, Amount", "terseLabel": "Commitment amount" } } }, "localname": "ShortTermLeaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r102", "r113" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies Basis of presentation" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r33", "r34", "r35", "r104", "r106", "r133", "r134", "r135", "r137", "r139", "r145", "r146", "r147", "r204", "r263", "r267", "r268", "r269", "r272", "r273", "r296", "r297", "r301", "r305", "r312", "r465", "r611" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r59", "r75", "r76", "r77", "r114", "r115", "r116", "r120", "r127", "r129", "r144", "r205", "r312", "r314", "r374", "r375", "r376", "r411", "r412", "r453", "r472", "r473", "r474", "r475", "r476", "r477", "r575", "r576", "r577", "r621" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/Disclosure21SubsequentEventsAdditionalInformationDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesAssumptionsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesChangesInFairValueDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetailsParentheticals", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-liability-and-equity-components-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-warrants-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-compensation-expense-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-assumptions-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r114", "r115", "r116", "r144", "r531" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/Disclosure21SubsequentEventsAdditionalInformationDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesAssumptionsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesChangesInFairValueDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote20CommitmentsAndContingenciesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetailsParentheticals", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote8AssetsHeldForSaleSummaryOfAssetsHeldForSaleDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-11-unsecured-convertible-debentures-liability-and-equity-components-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-warrants-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-compensation-expense-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stock-based-compensation-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-assumptions-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-outstanding-and-exercisable-options-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-and-rates-of-equipment-details", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-intangible-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r34", "r35", "r314" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Common shares issued in relation to merger with Grace via share-for-share (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r34", "r35", "r312", "r314" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "us-gaap_StockIssuedDuringPeriodSharesNewIssues", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)", "verboseLabel": "Net proceeds from shares issued under the at-the-market (ATM) program (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/Disclosure21SubsequentEventsAdditionalInformationDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r34", "r35", "r312", "r314" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock based compensation (in shares)", "terseLabel": "Stock based compensation (in shares)", "totalLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r34", "r35", "r312", "r314", "r354" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised", "negatedLabel": "Exercised, number of options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-15-stockbased-compensation-activities-within-the-stock-option-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r59", "r312", "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Common shares issued in relation to merger with Grace via share-for-share" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r34", "r35", "r312", "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "us-gaap_StockIssuedDuringPeriodValueNewIssues", "verboseLabel": "Net proceeds from shares issued under the at-the-market (ATM) program" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r34", "r35", "r314", "r343", "r359" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock based compensation", "terseLabel": "Stock based compensation", "totalLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r35", "r40", "r41", "r106", "r187", "r204", "r465", "r495" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total Shareholder\u2019s equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets", "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r105", "r297", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r314", "r317" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity Note Disclosure" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote1NatureOfOperationDetailsTextual" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityPolicyTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.", "label": "Stockholders' Equity, Policy [Policy Text Block]", "terseLabel": "Other equity instruments" } } }, "localname": "StockholdersEquityPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r478", "r497" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/Disclosure21SubsequentEventsAdditionalInformationDetailsTextual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r478", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/Disclosure21SubsequentEventsAdditionalInformationDetailsTextual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r478", "r497" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/Disclosure21SubsequentEventsAdditionalInformationDetailsTextual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r496", "r498" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-21-subsequent-events-" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/Disclosure21SubsequentEventsAdditionalInformationDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote11DerivativeWarrantLiabilitiesDetailsTextual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-details-textual", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.", "label": "Summary of Tax Credit Carryforwards [Table Text Block]", "terseLabel": "Summary of Tax Credit Carryforwards" } } }, "localname": "SummaryOfTaxCreditCarryforwardsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceTables", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r404" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax losses carried forward" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceTables", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Tax Credit Carryforward [Line Items]", "terseLabel": "Notes Tables" } } }, "localname": "TaxCreditCarryforwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceTables" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceTables", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCreditCarryforwardTable": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.", "label": "Tax Credit Carryforward [Table]" } } }, "localname": "TaxCreditCarryforwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceTables" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote9GovernmentAssistanceUnrecognizedFederalTaxCreditsExpirationsDetails", "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r197", "r198", "r200", "r201", "r202", "r287", "r310", "r451", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r611", "r612", "r613", "r614", "r615", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetails", "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote6ShorttermInvestmentsMarketableSecuritiesDetailsParentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r385", "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "us-gaap_UnrecognizedTaxBenefits", "periodEndLabel": "End of year", "periodStartLabel": "Beginning of year:" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Positions taken in the current year", "terseLabel": "Positions taken in the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-18-income-taxes-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r149", "r150", "r151", "r152", "r153", "r154", "r155" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Significant accounting policies, estimates and judgments:", "verboseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "us-gaap_WarrantsAndRightsOutstanding", "verboseLabel": "Amount" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-note-12-capital-and-other-components-of-equity-warrants-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average number of shares outstanding (in shares)", "terseLabel": "Weighted average number of shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/statement-consolidated-statements-of-loss-and-comprehensive-loss" ], "xbrltype": "sharesItemType" }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r85" ], "calculation": { "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialExpensesFinancialIncomeExpensesDetails": { "order": 3.0, "parentTag": "acst_TransactionCostsRelatedToDerivativeWarrantLiability", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.", "label": "Write off of Deferred Debt Issuance Cost", "negatedLabel": "Write-off of deferred financing fees related to at-the-market (ATM) program", "terseLabel": "Write-off of deferred financing fees related to at-the-market (ATM) program" } } }, "localname": "WriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.acastipharma.com/20220331/taxonomy/role/DisclosureNote14NetFinancialExpensesFinancialIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196772" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2599-110228" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21459-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r334": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r335": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r381": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r382": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r426": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r455": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r479": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918705-209980" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r498": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r538": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r553": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r586": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r603": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r604": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r605": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r606": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r607": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r608": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r609": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r611": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r612": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r613": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r614": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r615": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r616": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r617": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r618": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r619": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" } }, "version": "2.1" }